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Abstract
During the COVID-19 pandemic, laboratories experienced
periods of shortages for certain critical materials required to
meet the high demand for SARS-CoV-2 testing. The U.S.
Food & Drug Administration provided a template for molecular
diagnostic testing, including guidance for a specimen pooling
process in order to evaluate performance of the SARS-CoV-2
nucleic acid amplification assay. This study aimed to evaluate

the testing of pooled specimens consisting of four nasopharyngeal swab specimens using the Luminex ARIES® nucleic
acid amplification platform. Results indicated that there was a
loss of analytic sensitivity with pooled nasopharyngeal swab
samples, demonstrating that this approach should be balanced against material shortages and the clinical utility of a
less sensitive assay.

Introduction

samples if the positivity rate in the target population
was less than 5–6% as recommended by U.S. FDA.[2]
In this way, true savings of materials, time, and labor
costs would be realized.

When the World Health Organization (WHO) declared
COVID-19 a pandemic in March 2020 [1], the demand
for laboratory testing increased dramatically. This high
demand for testing placed considerable pressure on
healthcare providers and especially clinical laboratories to collect, process, and test the recommended respiratory samples, with nasopharyngeal swabs (NP) being the “gold standard.” Simultaneously, device manufacturers needed to rapidly deploy viral transport media, instruments, kits, and reagents to their customers
under the U.S. Food & Drug Administration (FDA)
emergency use authorization (EUA) guidelines. Due
to these factors, competition for limited supplies led
to periodic shortages of real-time reverse transcriptionpolymerase chain reaction (RT-PCR) materials for clinical laboratories. The placement of clinical laboratories on allotment of viral transport media, test kits,
reagents, swabs, and other critical supplies challenged
the workflow, limiting the number of tests that could
be performed. The University of Louisville (UofL) Infectious Diseases Laboratory experienced shortages in
carrier RNA, primers and probes, aerosol barrier tips
for micropipettes, and vendor-specific RT-PCR master
mix and cassettes at various time points in 2020 due
to the pandemic. One possible solution to the material shortages was to consider pooling of respiratory
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Following the FDA EUA guidance for molecular diagnostic testing (updated on July 28, 2020), the UofL
Infectious Diseases Laboratory evaluated the positivity rate for SARS-CoV-2 in various populations being
tested by Luminex ARIES® individual real-time RTPCR assay for SARS-CoV-2. The impact on the sensitivity of the assay if four respiratory samples were pooled
prior to testing was determined; results of pooled tests
were compared to individual real-time RT-PCR assay results for SARS-CoV-2 on the Luminex ARIES®
platform.[3] The aim of this study was to determine
whether pooling of NP specimens was a viable option
to reduce the total number of testing components required for real-time PCR detection of SARS-CoV-2.

Materials and Methods
Real-time RT-PCR assay for SARS-CoV-2
The UofL Infectious Diseases Laboratory validated a
TaqMan real-time RT-PCR assay for SARS-CoV-2 with
NP specimens tested individually. The reagents, in-
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strument, and assay settings for pooled testing were
the same as for individual sample testing as previously described for the Luminex ARIES® .[3, 4] The
limit of detection (LOD) was the cycle threshold (Ct)
value at which 100% of the individually tested NP specimens were positive in triplicate, and this final LOD
concentration was confirmed by testing 24 individual
replicates. Briefly, the established LOD Ct value for
N1 was 33.6±0.56 (range 33.04–34.16) and for N3 was
32.3±0.36 (range 31.94–32.76) for individual NP specimen PCR, which was equal to 1.5 tissue culture infective dose-50% (TCID50 )/mL of SARS-CoV-2. The positive control material used was heat-inactivated viral
culture fluid (CFHI-0.5 mL, Zeptometrix, Buffalo, NY).
Because SARS-CoV-2 could be detected in clinical samples (confirmed as positive by another method) beyond
the LOD of the assay as determined using a quantitated
commercial positive control (listed above), the amplification Ct cutoff value for nucleocapsid gene N1 was 38,
the Ct cutoff value for nucleocapsid gene N3 was 37,
and the Ct cutoff value for RNase P was 45, to avoid
missing any positive specimens at this early point in
the pandemic (March 2020). The Ct cutoffs for each
target were determined using the LOD data and from
60 confirmed positive and negative clinical specimens.
Furthermore, if either N1 or N3 was detected, and the
RNase P internal control was detected, the test was repeated in duplicate. If either one of the nucleocapsid
targets was repeatedly detected, then the result was reported as “presumptive positive” for patient management purposes and for the benefit to public health.
Sample pooling process
Groups of four NP specimens were placed in a rack in
a biosafety cabinet. Each group of four was labeled as
Pool A, Pool B, Pool C, etc., until all the pools were created. The unique identification of each sample in the
pool was recorded on worksheets. Each specimen was
vortexed prior to removing 500 µL, which was placed
in a sterile 15 mL tube for a final volume of 2 mL per
pool. Each pool was vortexed again; then, 195 µL of the
pool was transferred to a microcentrifuge tube containing 5 µL of 1 µg/1 µL carrier RNA in AVE buffer (QIAGEN, Germantown, MD). Next, 200 µL of this mixture was placed in an ARIES® cassette connected with
ReadyMix® tubes containing 5 µL of primer/probe set
for SARS-CoV-2 real-time RT-PCR testing. Individual
samples were stored in the refrigerator until pool testing was complete. If a pool resulted positive, then each
individual sample in the pool was retested. Groups of
three NP specimens were prepared in the same manner,
with the total “n-1 pool” equaling 1.5 mL. Because deidentified samples were used and no individually identifiable information was obtained, this method validation study was deemed exempt from institutional review board (IRB) requirements.
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Choice of population for pooling of specimens
The UofL Infectious Diseases Laboratory created reports in REDCap® , the Laboratory’s information management system [5, 6], to determine positivity rates
from different populations being tested for SARS-CoV2.[7] At the time of the evaluation, the health care
worker and hospitalized patient populations had a positivity rate greater than 6% (data not shown), so the
laboratory chose to pool NP swabs from patients of
the UofL Division of Infectious Diseases Travel Clinic.
These patients were generally healthy and asymptomatic, only being tested for the purposes of travel,
workplace surveillance, or elective surgery; thus, positivity rates were well below 6% for this population.
Therefore, the UofL Travel Clinic population met the
FDA criteria to perform the SARS-CoV-2 pool test validation.
Analytical validation
All steps were followed as outlined in the FDA EUA
guidance, updated on July 28, 2020.[2] Briefly, 100
Ct values for N1 and N3 targets from individually
tested SARS-CoV-2-positive NP specimens were examined to determine the number of specimens with Ct
scores close to the Limit of Detection. Next, 80 negative NP specimens previously tested by the ARIES®
real-time RT-PCR assay and individually negative for
SARS-CoV-2 were used to create pools of 4 to verify
that they remained negative when tested in pools. To
compare the results of pooled specimens to individual
test results, 48 positive NP specimens were analyzed
by combining 1 positive specimen with 3 known negative specimens (“n pools,” or 4 specimens total). Per
the FDA EUA guidance, 25% of the positive specimens
should be within 2–4 Ct values of the established N1
and N3 cutoff values. Finally, 26 samples were analyzed by combining 1 positive specimen with 2 known
negative specimens (“n-1 pools,” or 3 specimens total).
Analysis of data
Microsoft Excel was used to determine the positive
and negative agreement, comparing the performance
of tests for pooled samples vs. expected results from individual tests. The MedCalc Diagnostic Calculator was
used to determine analytic sensitivity and specificity.[8]
Agreement between pooling and undiluted or “neat”
samples, based on uncategorized Ct value thresholds,
was assessed through unweighted and weighted Cohen’s Kappa. Simple linear regression analysis was
performed to evaluate the shift in Ct values for N1 and
N3 for the positive patient samples diluted with the
negative patient samples (“n pool,” or 4 total samples).
Cohen’s Kappa and linear regressions were performed
using R version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria).
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Table 1. Percentage of positive agreement (“n pool,” 4 samples).

Result interpretation
SARS-CoV-2 DETECTED
SARS-CoV-2 Not Detected

Individual positive test results

Pools of 4 positive test results

48/48 (100)
0/48 (0)

40/48 (83.3)
8/48 (16.7)

All values reported as frequency/total (%).
Table 2. Percentage of positive agreement (“n-1 pool,” 3 samples).

Result interpretation
SARS-CoV-2 DETECTED
SARS-CoV-2 Not Detected

Individual positive test results

Pools of 3 positive test results

26/26 (100)
0/26 (0)

23/26 (88.5)
3/26 (11.5)

All values reported as frequency/total (%).

Results
We focused our pooling validation efforts on patients of
the UofL Division of Infectious Diseases Travel Clinic,
typically healthy people being screened for COVID-19.
This group of specimens gave our population a combined positivity rate of 1.78% (2/112), which was acceptable for the specimen pooling evaluation.
• Between May 4 and August 17, 2020, of 86 patients
screened prior to elective surgery, 0 (0%) were positive for SARS-CoV-2 by individual real-time RT-PCR
tests on the ARIES® instrument.
• Between July 24 and August 21, 2020, of 26 patients
screened in a single workplace, 2 (7.69%) were positive for SARS-CoV-2 by individual real-time RT-PCR
tests on the ARIES® instrument.
The FDA EUA guidance recommended several lines of
analysis. The starting point was to establish the laboratory’s range of Ct values for 100 NP specimens giving positive results for SARS-CoV-2. Evaluation of Ct
values for 100 NP specimens tested individually from
symptomatic patients collected between August 5 and
August 13, 2020, indicated that 22 specimens had Ct
values above the LOD range (weaker positives), 5 specimens had Ct values at the LOD, and 73 specimens had
Ct values below the LOD (stronger positives). Thus, we
observed 73% strong positive Ct values and 27% weak
positive Ct values during this time frame.
When 80 SARS-CoV-2 negative NP specimens were
tested both individually (80 results) and in pools of
4 (20 results), all real-time RT-PCR results remained
negative for SARS-CoV-2. The 100% negative agreement translated to no false positives, or 100% analytical
specificity.
To determine the percentage of positive agreement for
“n pools”, 48 previously positive SARS-CoV-2 speciULJRI | https://ir.library.louisville.edu/jri/vol6/iss1/1

mens (having a range of Ct values from 15.5 to 36.7 as
required by FDA) were re-tested both individually and
in pools with three negative samples (“n pool,” or four
samples). Per the FDA EUA Guidance, 25% of the 48
specimens were to be within 2–4 Ct values for N1 and
N3 targets when tested individually. Eight of these 48
previously positive NP specimens were not detected in
the “n pool” sample (Table 1). All eight Ct values were
near the established LOD when tested individually. Six
of these eight “false negative” specimens had Ct values above the LOD range (already weaker positives in
the individual assay), but below the cutoff values established for the individual real-time RT-PCR assay, while
the Ct value for one sample was within the established
LOD range, and one sample had a Ct value below the established LOD range. Thus, for NP specimens with Ct
values near the LOD when tested individually, pooled
testing may give false negative results.
To determine the percentage of positive agreement in
“n-1 pools” as recommended by the FDA EUA guidance, 26 previously positive SARS-CoV-2 specimens
(with a range of Ct values from 17.3 to 36.9 as required
by FDA) were re-tested both individually and in pools
with two negative samples (“n-1 pool”, three samples).
Per the FDA guidance, 25% of the 26 specimens were
to be within 2–4 Ct values of the Ct cutoff values for
N1 and N3 when tested individually. Three of these 26
positive samples were not detected in the “n-1 pool”
sample. The results of this analysis are shown in Table
2. Of the three samples not detected, all had Ct values
above the LOD (weaker positives) established for this
assay, but below the assay cutoff values. As expected,
we found that the sensitivity increased with smaller
pools of three rather than four specimens, improving
the percent positive agreement to 88.5% from 83.3%.
The next steps in the data analysis process were to use
statistical methods to determine the level of positive
detection agreement for each target (N1 and N3) for
pools of four NP specimens. As the groups could be
viewed as ranked/ordinal, weighted Cohen’s Kappa
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Table 3. N1 Ct values level of positive detection agreement (“n pool”, 4 samples).

Neat/undiluted

Pooled

LOD∗

Below LOD∗
Within LOD
Above LOD
Not Detected

Below
23
4
4
3

Within LOD
0
0
2
1

Above LOD
0
0
5
6

Not detected
0
0
0
0

Abbreviations: CI, confidence interval; Ct, cycle threshold; LOD, limit of detection.
∗ The established N1 LOD Ct was 33.6±0.56 (range 33.04–34.16). Percent agreement was 58.3%. Unweighted Cohen’s Kappa was 0.31 (95% CI 0.15–0.46), and
weighted Cohen’s Kappa was 0.53 (95% CI 0.35–0.722).
Table 4. N3 Ct values level of positive detection agreement (“n pool”, 4 samples).

Neat/undiluted

Pooled

LOD∗

Below LOD∗
Within LOD
Above LOD
Not Detected

Below
26
0
5
5

Within LOD
0
0
0
1

Above LOD
0
0
2
6

Not detected
0
0
1
2

Abbreviations: CI, confidence interval; Ct, cycle threshold; LOD, limit of detection.
∗ The established N3 LOD Ct was 32.3±0.36 (range 31.94–32.76). Percent agreement was 62.5%. Unweighted Cohen’s Kappa was 0.32 (95% CI 0.15–0.48), and
weighted Cohen’s Kappa was 0.51 (95% CI 0.26–0.76).

was appropriate to use for analysis. Both gene targets
indicated a statistically significant (determined by the
confidence interval) level of agreement between pooled
and individual testing; only the magnitude of agreement was different. In either case, the level of agreement could be described as fair (unweighted) to moderate (weighted) (Tables 3 and 4).
The final step in the data analysis process was to use
linear regression to calculate the average difference between individual and “n pool” specimen testing with
regard to detection of N1 and N3 targets. In this case,
the line of best fit represents the shift in Ct values for N1
or N3 from individual to “n pool” testing of NP specimens. The linear regression analysis demonstrated a
mean difference of 2.016 and a P-value <0.001 for N1.
This indicated that N1 Ct values from pools were on
average 2.016 higher than the N1 Ct values from individual testing (Figure 1). Similarly, linear regression
analysis of Ct values for N3 demonstrated a mean difference of 2.272 and a P-value <0.001. This indicated
that N3 Ct values from pools were on average 2.272
higher than the N3 Ct values from individual testing
(Figure 2).
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Discussion
The aim of this study was to evaluate the impact of
pooling four NP specimens prior to testing on the realtime RT-PCR assay’s sensitivity. The FDA guidance
recommended pooling samples when the target population’s positivity rate was less than 5–6% for true
savings to be realized. For example, if we chose to
pool 100 samples from a population with a 10% positivity rate, then 25 pools of four samples each would
be created. Assuming that ten patients of the 100 were
evenly distributed among the 25 pools, then ten of the
25 pools would need to be retested individually to find
the individual positive samples. Thus, the original 25
pooled tests plus 40 individual tests (from the ten positive pools) give a total of 65 tests instead of 100 individual tests. While this represents savings on materials, when compared to the staff time and labor spent
creating pools and breaking down pools, the savings
are not significant. Performing the same analysis with
a 5% positivity rate would reduce the total number of
tests from 100 to 45, which is significant.
After a target population with a less than 5-6% positivity rate was found, NP specimens were tested individually and in pools of four specimens first, then pools of
three, following U.S. FDA EUA guidance for method
validation. Positive predictive agreement for pools of
four NP specimens was 83%, while pools of three NP
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Figure 1. Linear regression of N1 Ct values between individual (neat)
and pool testing. The linear regression analysis of Ct values for N1
demonstrated a mean difference of 2.016 and a P-value <0.001.

Figure 2. Linear regression of N3 Ct values between individual (neat)
and pool testing. The linear regression analysis of Ct values for N3
demonstrated a mean difference of 2.272 and a P-value <0.001.

specimens improved to 88%. Linear regression data
analysis showed that for each gene target (N1 and N3),
there was a shift in Ct values between 2 and 3 when
comparing individual and pooled NP specimen testing
on the ARIES® instrument. Based on these results, the
UofL Infectious Diseases Laboratory would choose to
implement pooling under the following conditions: (1)
when the target population has a rolling weekly average of less than 5–6%; (2) when the persons being tested
are asymptomatic; and (3) when required kits, reagents,
or consumables are limiting for the real-time RT-PCR
assay for SARS-CoV-2.

rupted. Furthermore, the benefits of the ARIES® instrument were maintained, using a sample-to-answer protocol with a closed-system, reducing the risk of crosscontamination.

This study provided new information about the
ARIES® SARS CoV-2 assay with regard to the utility of
pooling when laboratory testing resources are limited.
One strength of the study was that a standardized, rigorous evaluation was performed following the criteria
set forth in the U.S. FDA EUA guidelines updated on
July 28, 2020. As a result, all of the data analysis indicated that an expected shift of 2–3 Ct values occurred
with pooling. After the evaluation was completed, a
total of 49 specimens were tested in 17 pools, consisting of 2–4 NP specimens from asymptomatic populations, using the validated SARS-CoV-2 pool assay. No
pools had detectable N1 or N3 RNA, but the internal
control RNaseP was detected in each pool. As a result, we demonstrated that pooling of four NP specimens (or fewer) was a viable alternative to individual
testing whenever laboratory supply chains are inter-
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Some limitations of the study were identified. The realtime RT-PCR laboratory-developed test for SARS-CoV2 using the Luminex ARIES® system is a multiplex assay, targeting N1, N3, and the internal control human
RNaseP. Using a multiplex assay potentially reduced
the analytic sensitivity when compared to a single target assay. In a single target assay, there is no primer
competition nor any potential “bleed over” between
fluorescent channels that may reduce sensitivity. In addition, since the test uses a sample-to-answer instrument, there is no separate RNA extraction or cDNA
synthesis step prior to the amplification step, possibly
affecting analytic sensitivity compared to multi-step
procedures. For example, using the ARIES® system, a
fixed volume of the sample must be added to the cartridge. With a separate extraction step, the amount of
nucleic acid can be quantified and normalized prior to
reverse transcription and PCR amplification to account
for samples with low viral loads. One study demonstrated that up to 30 samples could be pooled if RNA
was extracted prior to the RT-PCR step.[9] Finally, during the time frame in which this study was performed,
testing demand was high, and resources were limited,
so a full validation with data analysis for pools of three
NP specimens was not pursued.
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While the loss in analytical sensitivity was expected
with pooling of four NP specimens, further study of the
correlation of Ct values with clinical signs, symptoms,
and transmissibility is warranted. Two studies early in
the pandemic indicated that specimens tested by realtime RT PCR assays and having Ct values higher than

33–34 [10] or 35 [11] were unlikely to have cultivable
virus and thus were less likely to be infectious. Repeating these viral cultivation studies with pooled specimens would provide additional data regarding the impact of pooling specimens on clinical sensitivity and
patient management decisions.
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9. Lohse S, Pfuhl T, Berkó-Göttel B, et al. Pooling of samples for testing for SARS-CoV-2 in asymptomatic people.
Lancet Infect Dis 2020; 20(11):1231-2. doi: 10.1016/s14733099(20)30362-5. PMID: 32530425.

4. Rao A, Goldstein DY, Wolk DM, Wolf LA. Development and
evaluation of two SARS-CoV-2 RT-PCR laboratory developed
tests on the ARIES® automated, sample-to-answer, real-time
PCR system. White Paper, 2020 12 March 2020.

10. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA
load as determined by cell culture as a management tool for
discharge of SARS-CoV-2 patients from infectious disease
wards. Eur J Clin Microbiol Infect Dis 2020; 39(6):1059-61.
doi: 10.1007/s10096-020-03913-9. PMID: 32342252.

5. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N,
Conde JG. Research electronic data capture (REDCap)—a
metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed
Inform 2009; 42(2):377-81. doi: 10.1016/j.jbi.2008.08.010.
PMID: 18929686.

ULJRI | https://ir.library.louisville.edu/jri/vol6/iss1/1

11. Singanayagam A, Patel M, Charlett A, et al. Duration
of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May
2020. Euro Surveill 2020; 25(32). doi: 10.2807/15607917.Es.2020.25.32.2001483. PMID: 32794447.

6

